A global subsidy for antimalarial drugs.

Area of Science:

• Global Health
• Pharmacoeconomics
• Infectious Disease Control

Background:

• Artemisinin-combination therapies (ACTs) are effective antimalarial drugs.
• The emergence and spread of drug-resistant malaria strains is a significant global health concern.
• Previous malaria treatments, like chloroquine, are no longer effective.

Purpose of the Study:

• To evaluate the potential of a global high-level subsidy for ACTs.
• To assess the impact of such a subsidy on drug affordability and accessibility.
• To determine the role of subsidies in delaying antimalarial drug resistance.

Main Methods:

• The study proposes a market-based economic model for drug subsidy.
• The model considers subsidies for ACT manufacturers meeting quality criteria.
• It analyzes the price differential between subsidized ACTs and unsubsidized monotherapies.

Main Results:

• A global subsidy can make effective antimalarial drugs widely available at affordable prices.
• Subsidized ACTs would be priced similarly to older, ineffective drugs like chloroquine.
• Higher prices for unsubsidized monotherapies would discourage their use, reducing resistance risk.

Conclusions:

• A global high-level subsidy is a pragmatic and powerful strategy for malaria control.
• This approach effectively addresses both drug accessibility and the threat of resistance.
• The subsidy mechanism leverages market forces to achieve public health goals.